Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin…
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin…
At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 3…
In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying…
Robust commercial demand, with softer early-stage demand due to biotech funding constraints Growth project portf…
In 2022, Lonza delivered CHF 6.2 billion sales and 15.1%1 CER sales growth CHF 2.0 billion CORE EBITDA resulted in a mar…
Lonza meets pressing market need by launching first ever coating-free capsule to support intestinal delivery of acid-sen…
In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a mar…
. Annual General Meeting to take place on 5 May 2022 at the company’s headquarters in Basel, Switzerland Albert M. Bae…
. Lonza appoints Christian Seufert as President of the CHI Division and member of the Executive Committee Christian br…
Lonza erzielt einen Umsatz von CHF 5.4 Milliarden und einem Umsatzwachstum von 20% (kWk)1 CHF 1.7 Milliarden Kern-EBIT…